TCGA-B6-A0X0-01A-21R-A115-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 132
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.510
- ESTROGEN_RESPONSE_EARLY+0.300
- MYC_TARGETS_V1+0.250
- ESTROGEN_RESPONSE_LATE+0.230
- WNT_BETA_CATENIN_SIGNALING+0.230
- OXIDATIVE_PHOSPHORYLATION+0.170
- DNA_REPAIR+0.150
- CHOLESTEROL_HOMEOSTASIS+0.110
- NOTCH_SIGNALING+0.110
- UNFOLDED_PROTEIN_RESPONSE+0.100
Top 10 suppressed
- ANGIOGENESIS-0.550
- INTERFERON_GAMMA_RESPONSE-0.510
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.450
- COMPLEMENT-0.420
- INTERFERON_ALPHA_RESPONSE-0.420
- ALLOGRAFT_REJECTION-0.350
- IL6_JAK_STAT3_SIGNALING-0.350
- INFLAMMATORY_RESPONSE-0.350
- KRAS_SIGNALING_UP-0.320
- PROTEIN_SECRETION-0.320
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR6013506 | — | cohortA2 | 0.867 |
| 2 | SRR12202489 | — | — | 0.844 |
| 3 | DRR168523 | — | — | 0.836 |
| 4 | TCGA-AC-A6NO-01A-12R-A33J-07 | — | B | 0.830 |
| 5 | TCGA-60-2716-01A-01R-0851-07 | — | cohortSQ1 | 0.816 |
| 6 | TCGA-E2-A15J-01A-11R-A12P-07 | — | B | 0.808 |
| 7 | R230 | — | — | 0.808 |
| 8 | SRR5088853 | — | — | 0.806 |
| 9 | SRR2016956 | — | — | 0.805 |
| 10 | cc1c7e4b-89a0-4d94-b9e5-293c2eacadd9 | — | — | 0.805 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.510 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.300 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.250 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.230 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.230 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.170 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.150 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.110 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.110 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.100 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.050 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.050 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.040 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.030 | Inavolisib | — uncovered |
| PEROXISOME | 0.030 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.020 | Temsirolimus | — uncovered |
| P53_PATHWAY | 0.010 | Idelalisib | — uncovered |